Last reviewed · How we verify

Unidad de Investigacion en Enfermedades Cronico-Degenerativas — Portfolio Competitive Intelligence Brief

Unidad de Investigacion en Enfermedades Cronico-Degenerativas pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
intranasal saline solution plus glycerol intranasal saline solution plus glycerol marketed Nasal decongestant/mucosal hydration agent Otolaryngology/Respiratory

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Unidad de Investigacion en Enfermedades Cronico-Degenerativas:

Cite this brief

Drug Landscape (2026). Unidad de Investigacion en Enfermedades Cronico-Degenerativas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/unidad-de-investigacion-en-enfermedades-cronico-degenerativas. Accessed 2026-05-17.

Related